Matches in SemOpenAlex for { <https://semopenalex.org/work/W4234639313> ?p ?o ?g. }
Showing items 1 to 63 of
63
with 100 items per page.
- W4234639313 endingPage "101" @default.
- W4234639313 startingPage "93" @default.
- W4234639313 abstract "OBJECTIVE:To review the currently available information on rosuvastatin in the treatment of primary hypercholesterolemia.DATA SOURCES:MEDLEY (2000–January 2001), MEDLIT, MEDLINE, EMBASE, SciSearch, Current Contents, Derwent, Drug, BIOSIS, Adis LMS Drug Alerts, and International Pharmaceutical Abstracts (1994–July 2001) were searched; unpublished data obtained from the manufacturer were also included.STUDY SELECTION:Studies evaluating rosuvastatin including abstracts, proceedings, and data on file from the manufacturer were considered for inclusion. English-language literature was evaluated for pharmacology, pharmacodynamics, pharmacokinetics, therapeutic use, and adverse effects of rosuvastatin. Additional relevant citations were used in the introductory material and discussion section.DATA EXTRACTION:English-language study abstracts selected for inclusion were limited to those on human subjects. Animal data were included only if human data were not available.DATA SYNTHESIS:Rosuvastatin, a new synthetic hydroxymethylglutaryl coenzyme A reductase inhibitor (HMG-CoA RI), recently completed Phase III clinical trials. At a dosage of 1–80 mg/d, the drug significantly reduced total cholesterol and low-density-lipoprotein cholesterol (LDL-C) and produced beneficial effects on other lipid parameters as well. Overall, rosuvastatin was well tolerated.CONCLUSIONS:In hypercholesterolemic patients, rosuvastatin reduced LDL-C and other lipid parameters to a greater degree than currently available agents. One advantage of rosuvastatin is that it achieves target LDL-C goals in a greater proportion of treated patients with similar adverse events compared with those treated with other HMG-CoA RIs. The potential to reduce risk for coronary heart disease events and decrease mortality as well as cost comparisons with currently used HMG-CoA RIs remains a subject of further investigation." @default.
- W4234639313 created "2022-05-12" @default.
- W4234639313 creator A5015205978 @default.
- W4234639313 creator A5047224567 @default.
- W4234639313 date "2002-01-01" @default.
- W4234639313 modified "2023-10-14" @default.
- W4234639313 title "Rosuvastatin for the Treatment of Patients with Hypercholesterolemia" @default.
- W4234639313 doi "https://doi.org/10.1345/1542-6270(2002)036<0093:rfttop>2.0.co;2" @default.
- W4234639313 hasPublicationYear "2002" @default.
- W4234639313 type Work @default.
- W4234639313 citedByCount "0" @default.
- W4234639313 crossrefType "journal-article" @default.
- W4234639313 hasAuthorship W4234639313A5015205978 @default.
- W4234639313 hasAuthorship W4234639313A5047224567 @default.
- W4234639313 hasConcept C104950815 @default.
- W4234639313 hasConcept C126322002 @default.
- W4234639313 hasConcept C134651460 @default.
- W4234639313 hasConcept C181199279 @default.
- W4234639313 hasConcept C185592680 @default.
- W4234639313 hasConcept C197934379 @default.
- W4234639313 hasConcept C2776839432 @default.
- W4234639313 hasConcept C2778163477 @default.
- W4234639313 hasConcept C2780035454 @default.
- W4234639313 hasConcept C2780499067 @default.
- W4234639313 hasConcept C2908737378 @default.
- W4234639313 hasConcept C535046627 @default.
- W4234639313 hasConcept C55493867 @default.
- W4234639313 hasConcept C71924100 @default.
- W4234639313 hasConcept C98274493 @default.
- W4234639313 hasConceptScore W4234639313C104950815 @default.
- W4234639313 hasConceptScore W4234639313C126322002 @default.
- W4234639313 hasConceptScore W4234639313C134651460 @default.
- W4234639313 hasConceptScore W4234639313C181199279 @default.
- W4234639313 hasConceptScore W4234639313C185592680 @default.
- W4234639313 hasConceptScore W4234639313C197934379 @default.
- W4234639313 hasConceptScore W4234639313C2776839432 @default.
- W4234639313 hasConceptScore W4234639313C2778163477 @default.
- W4234639313 hasConceptScore W4234639313C2780035454 @default.
- W4234639313 hasConceptScore W4234639313C2780499067 @default.
- W4234639313 hasConceptScore W4234639313C2908737378 @default.
- W4234639313 hasConceptScore W4234639313C535046627 @default.
- W4234639313 hasConceptScore W4234639313C55493867 @default.
- W4234639313 hasConceptScore W4234639313C71924100 @default.
- W4234639313 hasConceptScore W4234639313C98274493 @default.
- W4234639313 hasLocation W42346393131 @default.
- W4234639313 hasOpenAccess W4234639313 @default.
- W4234639313 hasPrimaryLocation W42346393131 @default.
- W4234639313 hasRelatedWork W1994607275 @default.
- W4234639313 hasRelatedWork W2011332381 @default.
- W4234639313 hasRelatedWork W2037169403 @default.
- W4234639313 hasRelatedWork W2038338711 @default.
- W4234639313 hasRelatedWork W2078991136 @default.
- W4234639313 hasRelatedWork W2079011911 @default.
- W4234639313 hasRelatedWork W2081013641 @default.
- W4234639313 hasRelatedWork W2132599032 @default.
- W4234639313 hasRelatedWork W2308863118 @default.
- W4234639313 hasRelatedWork W3126645840 @default.
- W4234639313 hasVolume "36" @default.
- W4234639313 isParatext "false" @default.
- W4234639313 isRetracted "false" @default.
- W4234639313 workType "article" @default.